The ‘Orphan Drug’ Boom
Science, patients driving surge in Rx research for rare diseases
By LINDA A. JOHNSON - AP Business Writer
Published: May 26, 2015
TRENTON, N.J. — The global pharmaceutical industry is pouring billions of dollars into developing treatments for rare diseases, which once drew little interest...
Subscribe Today!
Story Tags: 
USD
rare diseases
Vertex Pharmaceuticals Inc.
Cystic Fibrosis Foundation
Pfizer Inc.
disease
rare disease
Trenton
Novartis AG
WBB Securities
Bristol-Myers Squibb Co.
GlobalData
Novo Nordisk A
Columbia
FDA Phase
Rare Genomics Institute
social media
pharmaceutical industry
manufacturing difficulties
then seizures
lymphoma and pulmonary fibrosis
cancer

Go Back

Advertisement